Dexsome™ Technology

Dextran Liposome (Dexsome™) Formulation

liposomeDexsome is a patented solution containing dextran, liposomes and nutrients.  LMI-Vet, LLC has developed the Dexsome technology for various applications in veterinary medicine, covered under US Patent No 7,220,538: “Composition for Maintaining Organ and Cell Viability”, with patent protection in 24 countries.

LMI-Vet, LLC will continue to strengthen its patent portfolio by working with Corporate Partners and Universities.  In addition to patent protection, LMI-Vet, LLC has established internal know-how and trade secrets surrounding the Dexsome platform and Dexsome Intravenous Fluid technology.

 

About LiposomesAbout DextranPatents
liposome1Liposomes are spherical vesicles with a lipid bilayer, which can be used to package and deliver nutrients, pharmaceuticals, and other small molecules.  A liposome is made out of the same material as a cell membrane.  Cell membranes are composed of phospholipids, such as phosphatidylethanolamine and phosphatidylcholine. The name liposome is derived from Greek: ‘Lipos’ meaning fat and ‘Soma’ meaning body.  Liposomes should not be confused with micelles, which do contain lipids but only have a lipid monolayer.  More information about liposomes can be found by watching the video in the footer.
dextran IV solutionDextran is a complex branched glucan (polysaccharide) of varying length and size. The larger dextrans, which typically remain in intact vessels, are too large to pass through the vessel. Therefore, dextran given intravenously can be used as an osmotic agent in cases of hypovolemia and support blood flow.
US Patent No 7,220,538 (Covers Dexsome Intravenous Fluid); “Composition for Maintaining Organ and Cell Viability”; with patent protection in 24 countries.  Contact us should the viewer not open properly.